Galectin Therapeutics (GALT) Competitors $2.85 +0.05 (+1.79%) Closing price 04:00 PM EasternExtended Trading$2.85 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. KROS, TLRY, MNMD, ORGO, ZVRA, TYRA, TSHA, OPT, BCYC, and KURAShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Keros Therapeutics (KROS), Tilray Brands (TLRY), Mind Medicine (MindMed) (MNMD), Organogenesis (ORGO), Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Keros Therapeutics Tilray Brands Mind Medicine (MindMed) Organogenesis Zevra Therapeutics Tyra Biosciences Taysha Gene Therapies Opthea Bicycle Therapeutics Kura Oncology Keros Therapeutics (NASDAQ:KROS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Which has stronger earnings and valuation, KROS or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M165.80-$187.35M-$0.18-80.50Galectin TherapeuticsN/AN/A-$47.05M-$0.72-3.96 Does the media favor KROS or GALT? In the previous week, Galectin Therapeutics had 2 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.94 beat Galectin Therapeutics' score of 0.85 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Keros Therapeutics Positive Galectin Therapeutics Positive Do analysts recommend KROS or GALT? Keros Therapeutics presently has a consensus target price of $30.56, indicating a potential upside of 110.87%. Galectin Therapeutics has a consensus target price of $6.00, indicating a potential upside of 110.53%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, KROS or GALT? Keros Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Is KROS or GALT more profitable? Keros Therapeutics has a net margin of 1.96% compared to Galectin Therapeutics' net margin of 0.00%. Keros Therapeutics' return on equity of 0.75% beat Galectin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics1.96% 0.75% 0.69% Galectin Therapeutics N/A N/A -216.05% Do institutionals and insiders have more ownership in KROS or GALT? 71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKeros Therapeutics beats Galectin Therapeutics on 10 of the 15 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.22M$2.42B$5.52B$9.32BDividend YieldN/A1.79%4.25%4.05%P/E Ratio-3.969.1828.1519.68Price / SalesN/A737.05438.33100.29Price / CashN/A160.6835.5357.53Price / Book-1.704.698.235.67Net Income-$47.05M$30.99M$3.23B$257.51M7 Day Performance26.67%0.60%-0.01%0.52%1 Month Performance91.28%7.93%5.61%8.84%1 Year Performance13.10%-5.48%26.52%14.18% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics2.2548 of 5 stars$2.85+1.8%$6.00+110.5%+17.6%$177.22MN/A-3.969Positive NewsKROSKeros Therapeutics2.082 of 5 stars$13.40-0.4%$30.56+128.0%-72.1%$546.28M$3.55M-74.44100TLRYTilray Brands1.8648 of 5 stars$0.50-6.6%$1.92+280.7%-68.9%$542.20M$788.94M-0.482,650MNMDMind Medicine (MindMed)2.199 of 5 stars$7.20+0.4%$25.50+254.2%+3.2%$541.72MN/A-5.5840Positive NewsORGOOrganogenesis4.4734 of 5 stars$4.25flat$6.00+41.2%+39.4%$539.13M$482.04M-25.00950News CoverageAnalyst ForecastZVRAZevra Therapeutics3.0567 of 5 stars$11.27+15.7%$23.14+105.3%+105.3%$532.58M$23.61M-5.9320Trending NewsAnalyst RevisionHigh Trading VolumeTYRATyra Biosciences3.1012 of 5 stars$9.61-3.9%$30.83+220.8%-49.5%$530.90MN/A-5.9020TSHATaysha Gene Therapies3.9895 of 5 stars$2.34-4.5%$8.20+250.4%+2.9%$525.92M$8.33M-6.88180News CoverageOPTOpthea0.3808 of 5 stars$3.41+7.2%$1.33-60.9%+63.2%$524.84M$120K0.008Gap UpBCYCBicycle Therapeutics3.391 of 5 stars$7.17-3.5%$25.00+248.7%-66.0%$514.56M$35.28M-2.28240KURAKura Oncology4.5594 of 5 stars$5.68-3.1%$24.50+331.3%-73.1%$507.33M$53.88M-2.70130Positive News Related Companies and Tools Related Companies KROS Alternatives TLRY Alternatives MNMD Alternatives ORGO Alternatives ZVRA Alternatives TYRA Alternatives TSHA Alternatives OPT Alternatives BCYC Alternatives KURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredTrump has to finance $21 trillion. Here’s His Move…Trump needs $21 trillion to fund his agenda — and insiders believe he’s quietly preparing a major shift in the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
